Unique ID issued by UMIN | UMIN000041158 |
---|---|
Receipt number | R000047005 |
Scientific Title | Safety-verification test about long-term inhalation of aqueous chloride dioxide aerosol |
Date of disclosure of the study information | 2021/07/21 |
Last modified on | 2021/06/24 18:52:32 |
Safety-verification test about long-term inhalation of aqueous chloride dioxide aerosol
Safety-verification test about long-term inhalation of aqueous chloride dioxide aerosol
Safety-verification test about long-term inhalation of aqueous chloride dioxide aerosol
Safety-verification test about long-term inhalation of aqueous chloride dioxide aerosol
Japan |
Healthy adults
Adult |
Others
NO
To confirm whether a long-term inhalation of aqueous ClO2 aerosol could have adequate safety in vivo.
Safety
Adverse events, and incidence rate of side effects
1. Body weight
2. Subjective symptoms
3. Hematologic test (WBC)
4. Blood-biochemical test (AST, ALT, gamma-GTP)
5. Immunological test (CRP)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Prevention
Other |
Inhalation of aqueous ClO2 aerosol to the volunteer, for 12 weeks (not less than 4 hours a week).
20 | years-old | <= |
Not applicable |
Male and Female
(1) Healthy male/female adults.
(2) Expected person working at the CPCC Company office for not less than four hours a week.
(3) Volunteers who gave informed consent to take part in this trial after being provided with an explanation of our experimental protocol detail.
(1) Volunteers who are now under the other clinical tests with some kind of medicine and/or health food, or took part in those tests within four weeks after the current trial.
(2) Volunteers with current and/or previous medical history of serious diseases in respiratory system.
(3) Volunteers who donated their blood components and/or whole blood (200 mL) within a month to this trial.
(4) Males who donated their whole blood (400 mL) within the last three months to this trial.
(5) Females who donated their whole blood (400 mL) within the last four months to this trial.
(6) Males who will be collected in total of their blood (1200 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial.
(7) Females who will be collected in total of their blood (800 mL) within the last twelve months, after adding the blood amounts planning to be sampled in this trial.
(8) Others who have been determined as ineligible for participation in this trial, according to the principal/sub investigator's opinions.
30
1st name | Suguru |
Middle name | |
Last name | Fujiwara |
CPCC Company Limited
Division of Clinical Research
101-0047
4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-3112
cpcc-contact@cpcc.co.jp
1st name | Mitsuhiro |
Middle name | |
Last name | Fujimoto |
CPCC Company Limited
Planning & Sales Department
101-0047
4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-3112
cpcc-contact@cpcc.co.jp
CPCC Company Limited
BONDS Inc.
Profit organization
Institutional Review Board of Chiyoda Paramedical Care Clinic
2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan
03-5297-5548
IRB@cpcc.co.jp
NO
2021 | Year | 07 | Month | 21 | Day |
Unpublished
Completed
2020 | Year | 07 | Month | 20 | Day |
2020 | Year | 07 | Month | 17 | Day |
2020 | Year | 07 | Month | 22 | Day |
2020 | Year | 11 | Month | 11 | Day |
2020 | Year | 07 | Month | 20 | Day |
2021 | Year | 06 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047005